News

GSK falls as blood cancer drug likely headed for US rejection
GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...
GSK shares fall after blood cancer drug likely headed for U.S. rejection
GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug ...
FDA Committee Votes Against GSK Blood Cancer Drug Blenrep
The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of ...
STAT3h
FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback
FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...
GSK falls as FDA advisors vote against approving blood cancer drug
A group of independent advisors to the U.S. Food and Drug Administration (FDA) on Thursday voted against the approval of a combination drug regimen involving GSK’s (NYSE:GSK) blood cancer medicine ...